Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Rose Today

By Joe Tenebruso – Oct 22, 2020 at 6:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's COVID-19 vaccine development efforts took an important step forward.

What happened

Shares of Moderna (MRNA -1.76%) climbed 3.6% on Thursday after the drugmaker announced the completion of enrollment for its COVID-19 vaccine study. 

So what

Moderna has enrolled 30,000 people for the phase 3 trial for its coronavirus vaccine candidate, mRNA-1273. The biotech noted that 42% of the participants are from groups deemed to be at high risk of severe COVID-19 disease, including more than 7,000 Americans over the age of 65 and 5,000 people who are younger but have chronic diseases, such as severe obesity and diabetes.

A person wearing safety gear is working in a laboratory.

Moderna's stock rallied on Thursday as investors applauded its vaccine testing progress. Image source: Getty Images.

Importantly, Moderna also said that 37% of study participants are minorities, which the company believes helps to represent the broad diversity of the U.S. population.

Now what

Over 25,000 participants have already received their second dose of the experimental vaccine. Moderna said it will decide whether to ask the Food and Drug Administration for emergency use authorization after it collects two months of safety data on roughly half of the study's participants.

Moderna is competing with the likes of Pfizer, AstraZeneca, Johnson & Johnson, and a host of other organizations in the race to find a safe and effective COVID-19 vaccine. Being first to market would give the winner advantages in terms of initial sales and development funding, and investors understandably cheered Moderna's potential progress in this regard.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.